Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by NEOS Investment Management LLC

NEOS Investment Management LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 21.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,256 shares of the biotechnology company's stock after purchasing an additional 8,674 shares during the quarter. NEOS Investment Management LLC's holdings in Exelixis were worth $1,640,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. USA Financial Formulas acquired a new position in Exelixis in the fourth quarter valued at $32,000. Principal Securities Inc. increased its position in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares during the period. Kestra Investment Management LLC purchased a new stake in Exelixis during the 4th quarter valued at approximately $39,000. Brooklyn Investment Group acquired a new stake in Exelixis during the 3rd quarter worth approximately $42,000. Finally, UMB Bank n.a. grew its stake in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 553 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Activity

In other Exelixis news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company's stock, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the transaction, the director now directly owns 33,514 shares in the company, valued at approximately $1,248,396.50. This represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 over the last three months. 2.85% of the stock is currently owned by corporate insiders.

Remove Ads

Exelixis Stock Performance

NASDAQ:EXEL traded down $0.71 during mid-day trading on Thursday, hitting $36.33. 452,971 shares of the company's stock traded hands, compared to its average volume of 2,137,610. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $40.02. The company has a market cap of $10.17 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The firm's 50 day simple moving average is $35.80 and its 200 day simple moving average is $33.48.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Truist Financial upped their price target on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. Brookline Capital Management began coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a "buy" rating for the company. Piper Sandler lifted their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Oppenheimer cut shares of Exelixis from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Exelixis currently has an average rating of "Moderate Buy" and an average target price of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.